A study to collect blood and tissue samples from consenting patients who have been diagnosed with kidney cancer
What can we learn about kidney cancer from the DNA of people who have it?
What is this study about?
The purpose of the TRANSORCE study is to collect blood and surplus pathology samples from people with suspected or confirmed kidney cancer. The samples will later be tested to find out if they contain any genetic or other abnormalities that may cause kidney cancer or affect the way the cancer responds to treatment.
Patients may be asked to participate in TRANSORCE at one of two stages:
- Prior to an operation to remove a suspected kidney cancer
- After an operation to remove a kidney cancer.
If surgery has already been performed and a patient has been diagnosed as having a kidney cancer that has an intermediate or high risk of returning the patient will also be asked to consider taking part in another part of this study which is trying to find out the best way of treating kidney cancer like this. The other part of the study is called SORCE.
Type of study
Translational Research Study
Who is funding the study?
The charity Cancer Research UK, the Medical Research Council and the Institute of Cancer Research.
When is it taking place?
The study accrued 1635 patients between July 2007 and April 2013.
Where is it taking place?
1527 patients were accrued in the UK, and 108 in Australia.
Who is included?
Patients may be asked to take part in TRANSORCE at one of three time-points: Prior to surgery for kidney cancer; Post-surgery, patients with a Leibovich score of 0-2 inclusive (i.e. at low risk the of cancer returning); Post-surgery, patients with a Leibovich score of 3-11 (i.e. at intermediate or high risk of their cancer returning) at the same time as they are randomised in the SORCE trial.